 |
市場調查報告書
商品編碼
2058371
Gabapentin市場：按劑型、應用、分銷管道和地區分類Gabapentin Market, By Dosage Form, By Application, By Distribution Channel, By Geography |
||||||
2026年Gabapentin市場規模估計為39億美元，預計2033年將達58億美元。預計2026年至2033年，其複合年成長率將達5.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 39億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 5.80% | 2033年市場規模預測： | 58億美元 |
全球Gabapentin市場在全球神經系統疾病和疼痛管理藥物市場中佔據重要佔有率。該市場涵蓋了這種γ-氨基丁酸（GABA）類似物的品牌藥和非專利藥。加巴噴丁最初是作為一種抗驚厥藥物開發的，用於治療癲癇，如今已有許多仿單標示外用途，包括治療神經性疼痛、不寧腿症候群、各種神經系統疾病、焦慮症、纖維肌痛等。隨著人們對加巴噴丁應用的認知不斷提高，預計市場成長將加速。
市場動態主要受大型製藥公司和非專利生產商的激進定價策略、豐富的產品系列和全球化企業發展所驅動。由於潛在的濫用風險和對仿單標示外用藥的擔憂，該市場受到嚴格的監管，包括嚴格的核准流程和上市後監測。市場細分涵蓋速釋和緩釋製劑、各種劑量以及廣泛的適應症和分銷管道，包括已開發市場和新興市場的醫院、零售藥局和線上藥局。
市場動態
全球Gabapentin市場成長的主要驅動力是神經系統疾病和慢性疼痛的日益普遍。在許多國家，神經病變和各種神經性疼痛的發生率正在迅速上升，凸顯了對更有效治療方法的迫切需求。人口老化以及老年人群中糖尿病神經病變和帶狀皰疹後遺症神經痛的高發生率也促進了特定市場的成長。此外，Gabapentin在焦慮症、躁鬱症和睡眠障礙等領域的仿單標示外使用也推動了多個市場的成長。人們對該藥物在疼痛管理中的作用認知不斷提高，進一步加速了這些市場的成長。
然而，市場存在諸多限制因素。例如，專利到期後學名藥競爭加劇，導致品牌藥價格壓力增大，利潤率下降。監管機構對藥物濫用、成癮風險以及包括頭暈和認知障礙在內的副作用的負面評估也阻礙了市場發展。儘管如此，市場仍蘊藏著許多機遇，例如新興市場醫療基礎設施改善和醫療支出成長帶來的應用拓展、緩釋製劑和組合藥物等新型劑型的研發，以及對新療法應用的研究。
本次調查的主要特點
- 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數創建了全球Gabapentin市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
- 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份全球Gabapentin市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球Gabapentin市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 監管趨勢
- 主要進展
- 產業趨勢
第4章 全球Gabapentin市場：依劑型分類，2021-2033年
- 膠囊
- 藥片
- 口服液
- 其他
第5章 全球Gabapentin市場：依應用領域分類，2021-2033年
- 神經性疼痛
- 癲癇
- 不寧腿（RLS）
- 其他
第6章 全球Gabapentin市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球Gabapentin市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin Limited
- Amneal Pharmaceuticals
- Zydus Lifesciences
- Viatris Inc.
- Apotex Inc.
- Reddy's Laboratories
第9章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
Gabapentin Market is estimated to be valued at USD 3.9 Bn in 2026 and is expected to reach USD 5.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.9 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.80% | 2033 Value Projection: | USD 5.8 Bn |
The global gabapentin market is a substantial part of the global neurological and pain management pharmaceuticals market. The market includes branded and generic formulations of this gamma-aminobutyric acid (GABA) analog agent. Emerging as an anticonvulsant used to treat epilepsy, the marketed drug now has many off-label uses to treat nerve-related pain, restless leg syndrome, various neurological disorders, anxiety, fibromyalgia, and other disorders. Market growth is predicted to accelerate with more recognized uses.
Competitive dynamics in the market stem from the aggressive pricing practices, product portfolios, and global presence of large pharmaceutical companies and generic manufacturers. The market is tightly regulated with a strict process of approval combined with post-marketing surveillance in eye of fear of abuse potential and off-label use. Market segmentation features immediate release and extended-release stages, various strengths, and a wide number of indications and distribution channels including hospital, retail, and online pharmacy in developed and emerging markets.
Market Dynamics
The global gabapentin market is driven by soaring incidence of neurological and chronic pain conditions with many countries witnessing sharp ascent in the incidence of epilepsy and various forms of neuropathic pains beckoning the need for more effective treatments. The aging population and the high incidence of elderly suffering from diabetic neuropathy and post-herpetic neuralgias are also contributing to the growth of certain specific markets. Furthermore, the off-label uses of gabapentin in anxiety disorder, bipolar disorder and sleep disorder is also helping to propel the growth of various markets. Increasing recognition of the role of drugs in pain management is further fueling the growth of these markets.
However, a number of constraints are present in the market, such as generic competition becoming intense after patents expire, resulting in pricing pressure on, and lower profit margins for, branded products. Negative regulatory reviews in relation to misuse potential, dependent risk and side effect liability including dizziness and cognitive deterioration is also a hindrance. However, there are a number of opportunities for the market, such as increasing opportunities for use in emerging markets, aided by improving healthcare infrastructure and increasing healthcare expenditure, and the invention of new formulations, such as extended-release formulations and combination products, and investigations into new therapeutic uses.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global gabapentin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin Limited, Amneal Pharmaceuticals, Zydus Lifesciences, Viatris Inc., Apotex Inc., and Dr. Reddy's Laboratories
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global gabapentin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gabapentin market
Market Segmentation
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Capsules
- Tablets
- Oral Solutions
- Others
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Neuropathic Pain
- Epilepsy
- Restless Legs Syndrome (RLS)
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin Limited
- Amneal Pharmaceuticals
- Zydus Lifesciences
- Viatris Inc.
- Apotex Inc.
- Reddy's Laboratories
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gabapentin Market, By Dosage Form
- Global Gabapentin Market, By Application
- Global Gabapentin Market, By Distribution Channel
- Global Gabapentin Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Gabapentin Market, By Dosage Form, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral Solutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Gabapentin Market, By Application, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Neuropathic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Restless Legs Syndrome (RLS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Gabapentin Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Gabapentin Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
Gabapentin市場規模、佔有率和成長分析：按類型、劑型、分銷管道、應用和地區分類－2026-2033年產業預測
Gabapentin市場預測至2034年－按產品類型、類別、給藥途徑、購買方式、應用、最終用戶和地區分類的全球分析
Gabapentin市場：全球市場預測（依給藥途徑、製劑、劑型、通路、最終用戶和適應症分類）－2026-2032年
Gabapentin市場：策略洞察與預測（2026-2031年）
加巴噴丁市場－全球產業規模、佔有率、趨勢、機會和預測，按劑型、類型、應用、配銷通路、地區和競爭格局分類，2020-2030年預測
Gabapentin市場規模、佔有率、趨勢分析報告：按劑型、類型、應用、分銷管道、地區、細分預測，2025-2030 年